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ABSTRACT 
We performed a multicenter  study in order to validate the concept that a simple CGA can identify 
elderly DLBCL non-fit patients in whom curative treatment  is not better then palliation and  to 
analyse potential benefits of treatment modulation after further subdividing the non-fit category by 
CGA criteria. 
One-hundred-seventy-three patients aged > 69 treated with curative or palliative intent by clinical 
judgment only were grouped according to CGA in fit (46%), unfit (16%) and frail (38%) categories. 
Two-yr OS was significantly better in fit than in non-fit patients (84% vs 47%; P <.0001). Survival in 
unfit and frail patients was not significantly different. Curative treatment  slightly improved 2-yr OS 
in unfit (75% vs 44%), but not in frail patients (45% vs 39%).  
CGA was confirmed as very efficient in identifying elderly DLBCL patients who can benefit from a 
curative approach. Further efforts are needed to better tailor therapies in non-fit  patients. 
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INTRODUCTION 
In the last few years Comprehensive Geriatric Assessment (CGA) was recognized as an essential 
tool for clinicians that manage elderly people affected by aggressive diseases [1]. The definition of 
elderly is still a matter of debate in oncology. In patients with lymphoma the age limit more 
frequently used to discriminate between younger and older patients is 65 [2].  
It is no longer acceptable to exclude patients from intensive treatment with curative intent only on 
the basis of chronological age. Aging is highly individualized in terms of life expectancy, functional 
reserve and social support and treatment plans need to account for this diversity that can be better 
evaluated by a multidimensional approach [3]. 
Diffuse large B cell lymphoma (DLBCL) represents a typical example of neoplastic disease that 
can be cured with an aggressive program. The majority of these patients are over the age of 60 
years and the steady improvement of life expectancy will probably further increase their number in 
the future [2]. Therefore, trying to improve the survival  of  this category of patients represents one 
of the major challenges for the haematologists. CGA  proved to be an effective method to identify 
elderly DLBCL patients able to tolerate intensive treatment with curative intent, achieving  an 
outcome similar to the one of younger patients [4].  
However about one half of the elderly patients cannot benefit from a curative approach and their 
prognosis is still very poor independently of the treatment received. 
Although broad agreement exists among oncologists on the different aspects of geriatric 
assessment and on the instruments to use for evaluating elderly peoples performance, the 
categories of elderly patients that need to be identified are still debated and the interpretation of the 
results of CGA tests has not been standardized yet . In particular, since new and very effective 
treatments with a better tolerability profile like anti-CD20 monoclonal antibodies have become 
available,  the attempt to better define  non-fit patients  according to the extent of their limitations 
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could help clinicians to better tailor treatment trying to improve the efficacy  of therapies in this 
patient category.                                                  
Therefore the FIL launched a  multicenter prospective study to verify our previous results in a 
broader population  of DLBCL patients with the same clinical characteristics and to assess the 
potential usefulness of a comprehensive geriatric assessment that further divides non-fit patients in 
two different levels according to the severity  of their unfitness. 
 
PATIENTS AND METHODS 
All consecutive patients with diffuse large B cell lymphoma aged more than 69 years seen in 13 
Hematology departments of the Italian Lymphoma Foundation (FIL) were recorded during one 
year. CGA was performed during staging procedures after written informed consent through the 
application of the following instruments: 1) age>80 years; 2) comorbidity score according to the 
Cumulative Illness Rating Score for Geriatrics (CIRS-G) [5] and evaluated in all the 
organs/systems as follows: no problem—0, mild problem (may require treatment)—1, moderate 
disability or morbidity (treatment required)—2, severe, constant, significant 
disability/’’uncontrollable’’ chronic problems—3, extremely severe disability, immediate treatment 
required/end organ failure/severe impairment in function—4; 3) activity of daily living (ADL), that is, 
loss in any activity, including bathing, dressing, toileting, transferring, feeding, and continence [6]; 
4) instrumental activity of daily living (IADL), an indirect evaluation of functional abilities necessary 
for independent living through caregivers interview [7] . Patients were classified in the category of 
‘‘fit’’ patients if they had all of the following conditions: age <80, no limitations in ADL and IADL 
scores: ADL score 6 and IADL score 8, CIRS-G: no grade 3-4 comorbidities (hematological 
comorbidities were not investigated) and less than 5 grade 2 comorbidities. Patients were 
classified as ‘‘unfit” if they had all of the following conditions: age > 79, no limitations in ADL and 
IADL scores: ADL score 6 and IADL score 8, CIRS-G: no grade 3-4 comorbidities and less than 5 
grade 2 comorbidities. In addition patients aged <80  with ADL score of 5 and/or IADL score of 6-7, 
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and/or CIRS-G: no grade 3-4 comorbidities  and 5 to 8 grade 2 comorbidities were also classified 
as “unfit”. All other patients who did not meet the criteria for fit and unfit patients were classified as 
‘‘frail’’ [8] (Table I). The decision to treat a patient and the choice of the type and intensity of 
treatment were always left to the clinical judgment of the attending physician, according to the 
policy of the Institution. Treatment with curative intent was defined as the use of a combination of 
an anthracycline-based chemotherapy (either liposomal or standard formulation), consisting of 
CHOP or CHOP-like regimens with rituximab,  delivered at a relative dose intensity greater than 
70% of the full dose as intent-to treat. Patients considered unable to tolerate such treatment 
received other  treatments  including radiation therapy only, low-dose chemotherapy without 
anthracyclines (cyclophosphamide, Oncovin [vincristine], and prednisone [COP], low-dose COP), 
rituximab as a single agent, corticosteroids alone, oral monochemotherapy or anthracycline-based 
cycles at  a relative dose intensity less than 70%, which were all defined as palliative therapy.  
The purpose of the study was to evaluate the outcome of the consecutive patients both considering 
the intensity of  treatment received and the results of CGA assessment. 
Statistical analyses were performed using Prism software (GraphPad Software, La Jolla, Calif). 
The overall survival (OS) time was computed from the initiation of therapy to the last visit that the 
patient was known to be alive or death from any cause and was evaluated according to the 
Kaplan–Meier method [9]. The characteristics of the subgroups of patients subdivided according to 
the type of treatment received and to CGA categorization were compared using Fisher exact test, 
Student t test, and Mann-Whitney statistics, as appropriate. Log-rank analysis was used to 
compare actuarial survival curves [10].The multivariate analysis of survival was performed using 
the Cox proportional hazard ratio (HR) [11] and 95% confidence interval (CI), taking into account 
all variables that had been shown to be significantly associated with survival in the univariate 
analysis. 
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RESULTS 
From September 2009  to August 2010, 177 patients aged more than 69 and affected by DLBCL 
were consecutively registered and  173 of them had fully evaluable data to be considered for the 
present study. According to CGA, 79 (46%) patients were classified as ‘‘fit’’, 28 (16%) as “unfit” and 
66 (38%) as “frail”. Two fit, one unfit and 1 frail patients were lost to follow up. Among unfit 
patients, 50% were aged more than 79 without any other limitation, 15% had one or two limitation 
in IADL only, 23% in IADL and ADL and 12% in IADL with more than 4 comorbidities of grade 2. 
Among frail patients 13% were aged more than 79 and unfit, 15% had one or more comorbidities of 
grade 3, 2 patients had only serious limitation in IADL while all the other patients had limitations in 
two or more assessment scales.  The main demographic and  clinical characteristics of this 
geriatric population are reported in table II. Fit patients were significantly younger compared with 
unfit and frail patients (p<0.0001), while no significant difference concerning stage, B symptoms 
and International Prognostic Index (IPI) was observed. All but five fit patients (94%) received a 
curative treatment:  one died before receiving any treatment,  three patients with stage I disease 
received only radiation therapy and one patient with stage II disease received  radiation and 
immunochemotherapy without antracycline  because of  previous treatment for breast cancer. With 
a median follow up of 24 months, their 2-year OS was significantly better  than survival of  non-fit 
patients (84% vs 47%) (P <0.0001). Among unfit and frail patients 2-year survival was 63% vs 40% 
respectively (p 0.13) (Figure 1).  
On the basis of clinical judgment, 17 unfit patients (61%) and 18 frail patients (27%) received full-
dose therapy with curative intent, and the remaining patients received palliation. Clinical 
characteristics of patients subdivided according to the treatment actually received are shown in 
table III. Patients treated with curative intent were significantly younger than patients receiving 
palliation (p 0.001) and had a more advanced stage (p 0.02) while no other significant differences 
were recorded.  
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Considering patients treated with curative intent overall, the survival of fit patients was significantly 
better than survival of non-fit patients (88% vs 56%) (p 0.0001).  
Within the single CGA categories, the 2-year overall survival of patients treated with curative or 
palliative intent   was 88% vs 25% (p 0.0001) in fit , 75% vs 45% (p 0.32) in unfit, and  44% vs 39% 
(p 0.75) in frail patients respectively (Figure 2).  
The rate of non hematologic toxicity of grade > 2 was not significantly different among patients 
treated respectively with curative or palliative intent (45% vs 38%; p 0.3). Lymphoma was the main 
cause of death in both treatment groups. 
At univariate analysis, age, IPI, CGA, ADL, IADL, CIRS-G, treatment approach (curative vs 
palliative) and treatment dose-intensity (cut-off 70%) were significantly associated with overall 
survival. Within a multivariate analysis only IPI and CGA maintained their strong association with 
overall survival (Table IV).  
 
DISCUSSION 
The results of our study confirm that CGA is a strong independent predictor of overall survival [12, 
13] and  can be usefully applied to the treatment decision in elderly patients with DLBCL.  
We adopted age 70 as the lower limit of clinical senescence since the prevalence of age-related 
changes is represented by an almost flat line up to this age and  increases sharply with older age 
[3, 14]. 
We used a modified score originally proposed by Balducci [3] that we have validated in a small 
population of elderly DLBCL patients [4] and that Spina et al. already proposed in a modified 
version. The primary aim  was to try to further divide the category of frail patients in order to 
modulate treatment intensity. A fully standardized geriatric assessment tool is not yet available. 
Therefore any choice in the subdivision of the geriatric categories is somewhat arbitrary. However 
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the criteria we applied referred to validated rating scales and to previously published papers [4, 
15].  
Only  short and rapid screening instruments  could be widely accepted in the oncology clinical 
practice [16, 17].This test is easy to perform and did not require more than 15 minutes. Trained  
clinicians and nurses can work  together according to their skills, assigning respectively the 
comorbidity and ADL/IADL scores. The most important warning is to avoid defining a patient as 
frail because of a reduced performance status depending only on his advanced and symptomatic 
disease. This may carry a significant risk of undertreating the patient.  
More recently a great interest has been directed on the prognostic role of nutritional parameters in 
the outcome of geriatric cancer population. Following the observation of the close correlation 
between hypoalbuminemia and survival in elderly patients with DLBCL [18], sarcopenia was 
studied in this category of patients and was found a strong predictor of overall survival, but this 
approach is still not easily applicable in the worldwide clinical practice [19]. 
The results of this study, far from being a final recommendation to be adopted in clinical practice, 
represent a further step toward the development of a simple geriatric score able to define different 
categories of elderly DLBCL patients suitable for different treatment intensity. 
 According to the standard protocols for elderly patients with DLBCL [20], the combination 
chemotherapy with CHOP or CHOP-like regimens with rituximab was chosen as the treatment 
strategy with curative intent.  A relative dose intensity of more than 70% of the standard dose was 
considered acceptable to maintain its therapeutic effect, as already demonstrated [21]. 
Only patients classified as fit by CGA had a very satisfactory clinical outcome using intensive 
curative approach . The 2-year OS rates of 88%, did not differ from the results achieved in younger 
patients with the same treatment [22, 23]. Moreover, major toxic effects were limited, and only 2 
patients died of treatment-related toxicity. The benefit of curative versus palliative treatment was 
lost in non-fit patients who had  a poor outcome irrespectively of the type of treatment received. 
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The same results were obtained in a recent study by Marchesi et al who used a similar simplified  
CGA [24]. In our paper frail patients had more frequently worse IPI score and stage B than fit 
patients, although the difference was not significant; however significant better survival of fit 
compared to frail intensively treated patients was evident both in the subgroup of low and high IPI 
score, and in the subgroup of A and B stage,  eliminating possible bias (data not shown).  
Compared to frail patients the outcome of unfit patients was not significantly different. However, 
there was a clear trend to a better survival, especially in the subgroup treated with curative intent. 
While the small number of unfit patients identified by CGA criteria may have limited the statistical 
power of the study, these results suggest that efforts in modulating the treatment intensity in this 
intermediate category of patients might be worthwhile in order to further improve their outcome and 
to reduce the number of elderly patients who might benefit of palliative care only. Modulation of 
chemotherapy according to  CGA  was already proposed by different authors [8, 13].  Spina et al. 
obtained interesting results adjusting the single chemotherapeutic agent according to comorbidities 
and total doses according to ADL/IADL. Attenuated immunochemotherapy regimen (R-miniCHOP) 
was used by the French group in elderly patients aged over 80 years without any other CGA 
parameter selection, obtaining a good compromise between efficacy and safety [18]. The 
combination of a lower dose of immunochemotherapy with a biologic drug could also be a valid 
alternative to be tested in a  clinical trial.  
In conclusion the CGA used in our study proved to be an efficient method to identify elderly DLBCL 
patients who can benefit from a curative approach with anthracycline-containing immuno-
chemotherapy.  It further suggests the potential usefulness of identifying different risk groups  in 
the category of  non-fit patients, by showing that a proportion of unfit patients exists who could 
obtain significant benefit when treated with curative intent. Therefore, new risk adapted strategies 
of treatment through modulated-intensity programs could reduce the difference of survival between 
fit and unfit patients and  clinical trials in this setting should be planned. Palliation seems the best 
choice for frail patients and improvement  of the supportive care is the only effort that could be 
proposed in this category of patients.  
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      Table I:  Definition of three geriatric risk categories according to age, comorbidities and functional  
       abilities of daily living 
CGA Categories Fit Unfit Frail 
ADL 6 5* < 4* 
IADL 8 7 – 6* < 5* 
CIRS-G 
no comorbidity      
score  3-4 
 and 
<5 comorbidities 
score  2 
no comorbidity 
score  3-4  
and 
5-8 comorbidities 
score  2 
>1 comorbidity        
score  3-4  
or 
> 8 comorbidities 
score 2 
Age  > 80 fit > 80 unfit 
      ________________________________________________________________ 
       NOTE. * number of residual functions  
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       Table II: Characteristics of patients classified according to CGA 
 
 
 
   
___________________________________________________________________ 
 
  NOTE. Data were available for 100% of patients in analysis except * Stage: missing data in 3%;  
   **B stage: missing data  in 30%; **IPI index: missing data in 6%. 
 
 
 
 
 
 
 
 
CGA category All Fit Unfit Frail 
P 
N° of evaluable patients (%) 173 79 (46%) 28 (16%) 66 (38%)  
M/F 91/82 52/27 13/15 26/40  
Median age 77 74 79 81 <0.0001 
Ann Arbor stage III-IV (%)* 57 57 58 58 NS 
Stage B (%)** 32 25 24 37 NS 
IPI risk class 
 Interm-high – high (%)*** 43 41 44 54 NS 
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           Table III: Characteristics of  unfit and frail patients subdivided according to the type of  
            treatment actually received based on clinical judgement 
 
TREATMENT CURATIVE PALLIATIVE P 
CGA categories UNFIT FRAIL UNFIT FRAIL  
N° of patients 17 18 11 48  
Median age 78 78 83 82 0.001* 
Ann Arbor stage III-IV 69% 78% 45% 49% 0.02* 
Stage B 33% 45% 10% 32% NS 
IPI risk class 
 Interm high/high 
56 58 30 52 NS 
ORR (CR + PR) 14 (82%) 13 (72%) 7 (64%) 25 (52%) NS 
Relapse Rate 2/14 4/13 2/7 5/25  
Lymphoma death 60% 80% 80% 84% NS 
Non hematologic 
 toxicity >2 
40% 50% 40% 33% NS 
           ______________________________________________________ 
              NOTE. * Comparison between all patients who received curative vs palliative treatment 
              Abbreviations: ORR, overall response rate; CR, complete remission; PR, partial remission 
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         Table IV: Overall survival time according to patient and treatment characteristics  (univariate   
         and multivariate Cox-regression analysis) 
Variables 
Univariate 
HR (95% CI) 
p-value 
Multivariate 
HR (95% CI) 
 
p-value 
Age <80 vs >80 years 2.67 (1.61-4.44) p 0.0002   
Stage I-II vs III-IV 1.59 (0.92-2.74) P 0.09   
IPI (Interm low/low vs 
Interm high/high) 
3.72 (1.80-7.68) p 0.0003 
4.60 
 (1.35-15.64) 
p 0.008 
CGA 5. 61 (2.95-10.64) P 0.0001 
3.69 
 (1.09-12.51) 
P 0.03 
ADL (< 5 vs 6) 0.3 (0.17-0.51) P 0.0001   
IADL (< 6 vs > 7) 0.24 (0.14-0.41) P 0.0001   
CIRS-G grade 2 
 (< 5 vs > 5) 
2.89 (1.04-8.03) P 0.04   
CIRS-G grade 3-4 
 (0 vs > 1) 
2.14 (1.22-3.73) P 0.007   
Curative vs palliative 
treatment approach 
0.27 (0.16-0.46) P 0.0001   
Treatment  dose: 
<70%  vs >70% 
0.38 (0.17-0.86) P 0.02   
 
         Abbreviations: HR, hazard ratio; CI, confidence interval 
 
 
 
 
